At $23.5 billion in market capitalization, Alexion has grown to become a major player in the biotech world, yet its current valuation does not give credit to the potential and pipeline of its overall business. And it seems Amgen has taken notice. Although there’s some pressure on Amgen to do a deal given the Bristol Myers’ recent acquisition of Celgene, the Alexion deal is attractive nonetheless...
Sorry, you need to subscribe to read this article.
If you would like to access this article, please subscribe below.
Premium subscribers receive complete access to our site content which includes market research and insights as well as coverage of the most important news, issues and events related to the healthcare technology industry.